Bristol-Myers Squibb and Pfizer filed multiple patent infringement suits in Delaware to protect patents for the profitable blood thinner, Eliquis.
The companies, which jointly develop the drug, filed suits against 13 generic drugmakers this week, plus three the week prior, who had planned to produce generic versions of Eliquis. Companies named include Mylan, Dr. Reddy’s Labs and Accord Healthcare.
In the Delaware litigation, BMS and Pfizer are seeking declarations that two patents for Eliquis are valid and enforceable, and allege the planned generics would infringe on one owned by Bristol-Myers Squibb and another owned by both companies.
Read the Delaware Law Weekly coverage